

[Stomach Neoplasms](#) [Gastroesophageal Junction Adenocarcinoma](#) [Gastric Cancer](#)

## A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

**Trial Status**  
**Terminated**

**Trial Runs In**  
**0 Countries**

**Trial Identifier**  
**NCT04933227 ML42913**

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study is designed to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with capecitabine plus oxaliplatin (XELOX) for first-line treatment in participants with HER2-negative unresectable advanced, recurrent or metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ AC).

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT04933227 ML42913**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
**All**

**Age**  
**>=18 Years**

**Healthy Volunteers**  
**No**